|
|
|
By Phillip Monk, Ph.D., Synairgen | There is still no approved antiviral therapy for adults with RSV infections. As drug developers, we need to prioritize developing new antiviral therapies for immunocompromised patients. |
|
|
|
| Complex Molecules, Complex Problems | Article | By Charles Johnson, Lonza | The support of an experienced CDMO is critical to overcoming complexity when working with a highly potent active pharmaceutical ingredient (HPAPI) and when solving solubility challenges. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIFE SCIENCE LEADER MAGAZINE |
|
|
|
Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business. |
|
|
